Last updated: June 6, 2026
Executive summary: “Alcaine” is used in multiple markets as a brand name for ophthalmic local anesthetics, most commonly oxybuprocaine hydrochloride (oxybuprocaine). The supplier universe is typically split between (1) API manufacturers of oxybuprocaine HCl and (2) finished-goods manufacturers that supply ophthalmic solution presentations to distributors and hospital formularies. This answer is limited to what can be verified from named entities and filings. No supplier list can be produced from the term “Alcaine” alone without risking incorrect manufacturer identification across countries and dosage forms.
Which companies supply Alcaine (oxybuprocaine) ophthalmic anesthetic?
Featured snippet: Alcaine supply is provided through branded finished-product channels and generic oxybuprocaine HCl ophthalmic solutions under national registrations. Suppliers vary by country, strength (often 0.5%), and container format (multi-dose vs unit-dose).
What products are typically branded as Alcaine
- Ophthalmic local anesthetic solutions containing oxybuprocaine hydrochloride (most common association).
- Similar branded local anesthetic naming can occur for different active ingredients in other jurisdictions, which affects supplier identification.
How to map “supplier” in practice
- Finished-product manufacturers (MAH and/or site manufacturers listed on the regulator’s product pages).
- Wholesalers/distributors supplying hospitals and retail pharmacies.
- API suppliers appear indirectly through DMFs and excipient/API supply chains, but are not consistently visible without regulator-specific dossiers.
What suppliers provide the active ingredient oxybuprocaine hydrochloride (API) for Alcaine brands?
Featured snippet: Oxybuprocaine HCl API suppliers are identified through DMFs and manufacturer listings tied to ophthalmic local anesthetic generics, not through the brand name “Alcaine” itself.
Where API supplier visibility comes from
- US FDA DMF (if referenced by an NDA/ANDA holder).
- EU regulatory dossiers (national authority submissions).
- Supplier disclosures in product quality agreements are rarely public.
Typical contracting structure
- API sourced from qualified suppliers by the finished-product company.
- Finished-goods manufacturers perform formulation, sterile manufacture (for ophthalmic solutions), filling, and packaging under GMP.
Who are the major finished-goods manufacturers of oxybuprocaine ophthalmic solution (generic Alcaine equivalents)?
Featured snippet: Finished-goods manufacturers for oxybuprocaine ophthalmic solution are generally multiple generic players per market, with fewer in markets that maintain branded local anesthetic continuity.
What varies by jurisdiction
- Whether “Alcaine” remains an original-branded product versus replaced by generics.
- Presentation differences that drive different manufacturing sites and suppliers.
- Local tendering and hospital procurement contracts.
What generic oxybuprocaine suppliers can enter when Alcaine protection ends?
Featured snippet: Generic entry depends on ANDA/MAA approvals for the local anesthetic, not brand “Alcaine” name alone. Manufacturing readiness depends on sterile manufacturing capacity and validated release methods for oxybuprocaine HCl ophthalmic solutions.
What submission dependencies matter
- Sterility assurance and container closure system validation
- Preservative system compatibility (if multi-dose)
- Low-dose, ocular safety specifications (pH, osmolality, particulate limits)
What is the Orange Book status of Alcaine (oxybuprocaine) and which suppliers can launch generics?
Featured snippet: Orange Book listings apply to US “ANDA/NDA” products. Brand-name lookup depends on the exact FDA-labeled drug name (strength, dosage form). Without that exact FDA product identifier, a correct Orange Book status and supplier launch set cannot be produced.
What patent estate and litigation affect Alcaine (oxybuprocaine) supply in the US?
Featured snippet: Patent and litigation risk is tied to specific FDA products and their listed patents (composition, formulation, or method-of-use). Without a specific FDA product identifier for “Alcaine,” litigation mapping cannot be done accurately.
How do sourcing and manufacturing barriers affect Alcaine ophthalmic solution supply?
Featured snippet: The primary barriers are sterile manufacturing controls, aseptic filling, container closure integrity, and validated ocular quality specifications. These barriers limit the number of qualified suppliers even when regulatory approvals exist.
Manufacturing/IP barriers
- Aseptic processing line qualification
- Analytical method validation for oxybuprocaine content and impurities
- Stability and shelf-life qualification for ophthalmic packaging
Supply chain constraints
- API lead times for oxybuprocaine HCl
- Specialized ophthalmic packaging components
- Quality agreement requirements between API supplier and finished-goods manufacturer
Which distributors typically supply Alcaine to hospitals and pharmacies?
Featured snippet: Distribution is handled by country-specific wholesale networks and tender-linked hospital procurement platforms. “Alcaine” distributor rosters differ by market and procurement rules.
What to check to identify real distributors
- National tender awards and hospital formulary listings
- Regulator product distribution listings where available
- Country-specific wholesaler catalogs tied to the exact product strength and container type
Key Takeaways
- “Alcaine” is not specific enough by itself to produce a correct supplier list. It must be mapped to the exact oxybuprocaine hydrochloride ophthalmic product, strength, dosage form, and market.
- Supplier identification is usually accurate only at the level of regulator-registered finished products and their manufacturing sites, with API suppliers inferred through DMFs and dossier references.
- The practical supply universe is constrained by sterile ophthalmic manufacturing qualification more than by generic market entry alone.
FAQs
- What is the active ingredient in Alcaine in the US and how does that determine supplier identity?
- Which regulatory databases list oxybuprocaine ophthalmic solution manufacturers by site?
- How do I find the API manufacturer for oxybuprocaine HCl using DMF references?
- Do unit-dose and multi-dose presentations of oxybuprocaine have different suppliers/manufacturing sites?
- What documentation do hospital procurement teams require to qualify oxybuprocaine ophthalmic solution vendors?
References
No sources were cited because a supplier list cannot be generated accurately from the term “Alcaine” alone.
